International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV) and the register “Analysis of hospitalizations of comorbid patients infected during the second wave of SARS-CoV-2 outbreak” (AKTIV 2)

Arutyunov, G. P.; Tarlovskaya, E. I.; Arutyunov, A. G.; Bockeria, Leo A.; Конради, А. О.; Lopatin, Yuri; Ребров, А. П.; Tereshchenko, S. N.; Чесникова, А. И.; Hayrapetyan, H. G.; Babin, A. P.; Бакулин, И. Г.; Бакулина, Н. В.; Балыкова, Л. А.; Blagonravova, A. S.; Болдина, М. В.; Vaisberg, A. R.; Galyavich, A. S.; Gomonova, V. V.; Grigoryeva, N. Yu.; Губарева, И. В.; Demko, I. V.; Evzerikhina, A. V.; Жарков, А. В.; Kamilova, Umida; Kim, Z. F.; Kuznetsova, Т. Yu.; Lareva, N.V.; Makarova, E. V.; Malchikova, S. V.; Nedogoda, S. V.; Петрова, М. М.; Починка, И. Г.; Protasov, К. V.; Protsenko, D.N.; Ruzanov, D. Yu.; Sayganov, S. A.; Sarybaev, A. Sh.; Selezneva, N. M.; Sugraliyev, Akhmetzhan; Фомин, И. В.; Khlynova, O. V.; Chizhova, O. Yu.; Шапошник, И. И.; Sсhukarev, D. A.; Abdrakhmanova, Aigul; Avetisian, S A; Avoyan, H. G.; Azarian, K. K.; Aimakhanova, G. T.; Ayipova, D. A.; Akunov, A. Ch.; Алиева, М. К.; Апаркина, А. В.; Aruslanova, O. R.; Ashina, E. Yu.; Badina, O. Yu.; Barysheva, O. Yu.; Batchayeva, A. S.; Bitieva, A. M.; Bikhteyev, I. U.; Borodulina, N. A.; Bragin, M. V.; Budu, A. M.; Burygina, L. A.; Bykova, G. A.; Varlamova, D. D.; Везикова, Н. Н.; Verbitskaya, E. A.; Vilkova, O. E.; Vinnikova, E. A.; Vustina, V. V.; Galova, Elena A.; Генкель, В. В.; Gorshenina, E. I.; Grigorieva, Elena V.; Gubareva, E. Yu.; Dabylova, G. M.; Demchenko, A. I.; Dolgikh, O. Yu.; Duvanov, I. A.; Duyshobayev, M. Y.; Evdokimov, D. S.; Egorova, K E; Ермилова, А. Н.; Zheldybayeva, A. E.; Заречнова, Н. В.; Ivanova, S. Yu.; Ivanchenko, E. Yu.; Ilina, M. V.; Казаковцева, М. В.; Kazymova, E. V.; Kalinina, Yu. S.; Kamardina, N. A.; Karachenova, A. M.; Каретников, И. А.; Кароли, Н. А.; Карпов, О. В.; Karsiev, M. Kh.; Kaskaeva, D. S.; Kasymova, K. F.; Kerimbekova, Zh. B.; Kerimova, A. Sh.; Kim, E. S.; Киселева, Н. В.; Klimenko, D. A.; Klimova, A V; Kovalishena, O. V.; Колмакова, Е. В.; Kolchinskaya, T. P.; Колядич, М. И.; Kondriakova, O. V.; Konoval, M. P.; Konstantinov, D. Yu.; Konstantinova, E. A.; Kordukova, V. A.; Королева, Е. В.; Kraposhina, A. Yu.; Крюкова, Т. В.; Кузнецова, А. С.; Kuzmina, T. Y.; Kuzmichev, K. V.; Kuprina, T. V.; Kouranova, I M; Kurenkova, L. V.; Kurchugina, N. Yu.; Kushubakova, Nadira; Levankova, V. I.; Levin, Michael; Lyubavina, N. A.; Magdeeva, N. A.; Mazalov, K. V.; Majseenko, V. I.; Makarova, A. S.; Kulchoroeva, Ch. K.; Marusina, A. A.; Melnikov, E. S.; Moiseenko, N. B.; Muradova, F N; Muradyan, R. G.; Musaelian, Sh. N.; Никитина, Н. М.; Ogurlieva, B. B.; Odegova, A. A.; Omarova, Yu. V.; Омурзакова, Н. А.; Ospanova, Sh. O.; Pakhomova, E. V.; Petrov, L. D.; Пластинина, С С; Pogrebetskaya, V. A.; Polyakov, D. S.; Ponomarenko, E. V.; Popova, L. L.; Prokofeva, N. A.; Пудова, И. А.; Rakov, N. A.; Рахимов, А. Н.; Rozanova, N A; Serikbolkyzy, S.; Simonov, A. A.; Skachkova, V. V.; Smirnova, L. A.; Soloveva, D. V.; Soloveva, Irina A.; Sokhova, F. M.; Subbotin, A. K.; Sukhomlinova, I. M.; Sushilova, A. G.; Tagayeva, D R; Titojkina, Yu. V.; Тихонова, Е. П.; Tokmin, D. S.; Torgunakova, M. S.; Trenogina, K. V.; Trostianetckaia, N. A.; Trofimov, D. A.; Туличев, А. А.; Tupitsin, D. I.; Tursunova, A. T.; Tiurin, A A; Ulanova, N. D.; Фатенков, О. В.; Fedorishina, Olga; Fil, T. S.; Fomina, I. Yu.; Fominova, I. S.; Frolova, I A; Tsvinger, S. M.; Tsoma, V. V.; Cholponbaeva, Meerim; Chudinovskikh, T. I.; Shakhgildyan, L. D.; Shevchenko, Olga; Sheshina, T V; Shishkina, Ekaterina; Shishkov, K. Yu.; Sherbakov, S. Y.; Yausheva, Ekaterina

doi:10.15829/1560-4071-2021-4358

Cited by 22 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ståhlberg et al introduced the term "post-COVID-19 tachycardia syndrome" to describe the presence of tachycardia in post-COVID syndrome, a specific phenotype of "post-acute COVID-19 syndrome", which is defined as symptoms persisting for 4-12 weeks or longer than 12 weeks after COVID-19 infection [ 13 ]. Thus, in patients included in the ACTIV registry, comorbid diseases comparable to those cited above were identified, leading to increased readmissions and mortality in the posthospital period [ 14 , 15 ]. Apparently, the dominant nature of cardiovascular diseases in patients in the post-hospital period of COVID-19 is universal in all regions of the world and raises questions about the possible affinity of the virus to certain tissues and organs.…”

Section: Discussionmentioning

confidence: 99%

Occurrence of comorbid diseases in patients after COVID-19

Kamilova,

Ermekbaeva,

Nuritdinov

et al. 2023

JMedLife

View full text Add to dashboard Cite

The COVID-19 pandemic has highlighted the potential impact of this disease on cardiovascular morbidity and mortality. Patients with established cardiovascular (CV) disease are at increased risk of severe infection and hospital-acquired adverse outcomes. This study aimed to investigate the prevalence and characteristics of comorbidities in COVID-19 patients. We analyzed data from 220 patients who previously contracted COVID-19. Statistical analysis was performed using SPSS software. The average age of the patients was 54.6 ± 11.4 years, and arterial hypertension (AH) was the most common comorbidity, affecting 55% of patients. Obesity was observed in one-third of patients, while coronary heart disease (CHD) and coronary heart failure (CHF) were reported in 17.7% and 11.8% of patients, respectively. Chronic kidney disease (CKD), atrial fibrillation (AF), and obstructive pulmonary disease (COPD) were less common. Cardiovascular diseases, particularly AH, were the most frequent comorbidities in COVID-19 patients. Understanding the prevalence and characteristics of comorbidities in COVID-19 patients is crucial for developing appropriate management strategies and improving clinical outcomes. Our findings highlight the importance of identifying and managing comorbidities in COVID-19 patients to reduce the risk of severe COVID-19 and improve clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Occurrence of comorbid diseases in patients after COVID-19

Kamilova,

Ermekbaeva,

Nuritdinov

et al. 2023

JMedLife

View full text Add to dashboard Cite

show abstract

“…Российский кардиологический журнал 2021; 26 (4) Цитокиновый шторм (ОШ 1,94 (95% ДИ 1,355-2,777) р<0,001) и бактериальная пневмония (ОШ 1,361 (95% ДИ 0,986-1,878)) также повышали риск летального исхода у пациентов с COVID-19. Таким образом, самыми частыми осложнениями у умерших пациентов были ОРДС (55,59%), ОПП (43,50%), цитокиновый шторм (35,97%).…”

Section: Discussionunclassified

International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19

Arutyunov¹,

Tarlovskaya²,

Arutyunov³

et al. 2021

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

The international AKTIV register presents a detailed description of out- and inpatients with COVID-19 in the Eurasian region. It was found that hospitalized patients had more comorbidities. In addition, these patients were older and there were more men than among outpatients. Among the traditional risk factors, obesity and hypertension had a significant negative effect on prognosis, which was more significant for patients 60 years of age and older. Among comorbidities, CVDs had the maximum negative effect on prognosis, and this effect was more significant for patients 60 years of age and older. Among other comorbidities, type 2 and 1 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, cancer and anemia had a negative impact on the prognosis. This effect was also more significant (with the exception of type 1 diabetes) for patients 60 years and older. The death risk in patients with COVID-19 depended on the severity and type of multimorbidity. Clusters of diseases typical for deceased patients were identified and their impact on prognosis was determined. The most unfavorable was a cluster of 4 diseases, including hypertension, coronary artery disease, heart failure, and diabetes mellitus. The data obtained should be taken into account when planning measures for prevention (vaccination priority groups), treatment and rehabilitation of COVID-19 survivors.

show abstract

“…A detailed description of the study design and statistical data processing methods has been published previously. 3 Further information about the ACTIV registry is available on the website of the Eurasian Association of Therapists or via a direct link ( https://ACTIV.euat.ru ).…”

Section: Methodsmentioning

confidence: 99%

Impact of heart failure on all‐cause mortality in COVID‐19: findings from the Eurasian International Registry

et al. 2022

Self Cite

View full text Add to dashboard Cite

Aims To study all‐cause mortality in patients hospitalized with COVID‐19 with or without chronic heart failure (CHF) during hospitalization and at 3 and 6 months of follow‐up. Methods and results The international registry Analysis of Comorbid Disease Dynamics in Patients with SARS‐CoV‐2 Infection (ACTIV) was conducted at 26 centres in seven countries: Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russian Federation, and Uzbekistan. The primary endpoints were in‐hospital all‐cause mortality and all‐cause mortality at 3 and 6 months of follow‐up. Of the 5616 patients hospitalized with COVID‐19, 917 (16.3%) had CHF. Total in‐hospital mortality was 7.6%. In‐hospital mortality was higher in patients with CHF than in patients without a history of CHF [17.7% vs. 4.0%, P < 0.001; odds ratio (OR) 4.614, 95% confidence interval (CI) 3.633–5.859; P < 0.001]. The risk of in‐hospital all‐cause mortality correlated significantly with the severity of CHF; specifically, the risk of in‐hospital all‐cause mortality was greater for patients in New York Heart Association functional classes III and IV (OR 6.124, 95% CI 4.538–8.266; P < 0.001 vs. patients without CHF) than for patients in functional classes I and II (OR 2.446, 95% CI 1.831–3.267, P < 0.001 vs. patients without CHF). The risk of mortality in patients with ischemic CHF was 58% higher than in patients with non‐ischaemic CHF [OR 1.58 (95% CI 1.05–2.45), P = 0.030]. In the first 3 months of follow‐up, the all‐cause mortality rate in patients with CHF was 10.32%, compared with 1.83% in patients without CHF ( P < 0.001). At 6 months of follow‐up, NYHA classes II–IV was a strong risk factor for all‐cause mortality [OR 5.343 (95% CI 2.717–10.508); P < 0.001]. Conclusions Hospitalized COVID‐19 patients with CHF have an increased risk of in‐hospital all‐cause mortality, which remains high 6 months after discharge.

show abstract

International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV) and the register “Analysis of hospitalizations of comorbid patients infected during the second wave of SARS-CoV-2 outbreak” (AKTIV 2)

Cited by 22 publications

References 9 publications

Occurrence of comorbid diseases in patients after COVID-19

Occurrence of comorbid diseases in patients after COVID-19

International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19

Impact of heart failure on all‐cause mortality in COVID‐19: findings from the Eurasian International Registry

Contact Info

Product

Resources

About